Bio-Path provides 2024 clinical update: AML, solid tumor trials advancing

BIO-PATH HOLDINGS, INC.

Phase 2 prexigebersen trial in AML targets FDA Fast Track for fragile patients; median survival 5-10 months.
Phase 1/1b BP1001-A in solid tumors advanced to second dose level; Phase 1b with paclitaxel planned.
Phase 1/1b BP1002 in relapsed/refractory AML enrolling at 40 mg/m2; no DLTs at 20 mg/m2.
Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort (40 mg/m2) after no DLTs.
Patent portfolio: 5 US and 53 foreign issued patents covering DNAbilize technology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.